S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
Log in

NASDAQ:NVCR - Novocure Stock Price, Forecast & News

$92.58
-1.80 (-1.91 %)
(As of 01/20/2020 04:00 PM ET)
Today's Range
$92.09
Now: $92.58
$95.52
50-Day Range
$74.97
MA: $84.08
$94.44
52-Week Range
$41.51
Now: $92.58
$98.70
Volume1.44 million shs
Average Volume968,198 shs
Market Capitalization$9.16 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.37
Novocure Ltd. is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVCR
CUSIPN/A
Phone44-0-15-3475-6700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$248.07 million
Book Value$1.21 per share

Profitability

Net Income$-63,560,000.00

Miscellaneous

EmployeesN/A
Market Cap$9.16 billion
Next Earnings Date2/27/2020 (Confirmed)
OptionableOptionable

Receive NVCR News and Ratings via Email

Sign-up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter.


Novocure (NASDAQ:NVCR) Frequently Asked Questions

What is Novocure's stock symbol?

Novocure trades on the NASDAQ under the ticker symbol "NVCR."

How were Novocure's earnings last quarter?

Novocure Ltd (NASDAQ:NVCR) announced its quarterly earnings data on Thursday, October, 31st. The medical equipment provider reported $0.02 EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.05) by $0.07. The medical equipment provider earned $92.06 million during the quarter, compared to analysts' expectations of $87.12 million. Novocure had a negative net margin of 8.43% and a negative return on equity of 18.45%. The business's revenue for the quarter was up 42.2% compared to the same quarter last year. During the same quarter last year, the business earned ($0.13) earnings per share. View Novocure's Earnings History.

When is Novocure's next earnings date?

Novocure is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Novocure.

How can I listen to Novocure's earnings call?

Novocure will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Novocure issued on next quarter's earnings?

Novocure updated its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $351.3-351.3 million, compared to the consensus revenue estimate of $347.69 million.

What price target have analysts set for NVCR?

6 brokerages have issued 1-year target prices for Novocure's shares. Their forecasts range from $50.00 to $97.00. On average, they anticipate Novocure's share price to reach $80.33 in the next twelve months. This suggests that the stock has a possible downside of 13.2%. View Analyst Price Targets for Novocure.

What is the consensus analysts' recommendation for Novocure?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novocure.

Has Novocure been receiving favorable news coverage?

Media coverage about NVCR stock has been trending extremely negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Novocure earned a coverage optimism score of -5.0 on InfoTrie's scale. They also gave news articles about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Novocure.

Who are some of Novocure's key competitors?

What other stocks do shareholders of Novocure own?

Who are Novocure's key executives?

Novocure's management team includes the folowing people:
  • Asaf Danziger, Chief Executive Officer & Director
  • Mike Ambrogi, Chief Operating Officer
  • Wilco Groenhuysen, CFO & Chief Accounting Officer
  • Eilon D. Kirson, Chief Science Officer, Head-Research & Development
  • Uri Weinberg, Vice President-Clinical Development

Who are Novocure's major shareholders?

Novocure's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.35%), Peregrine Capital Management LLC (0.15%), Polianta Ltd (0.01%), Sciencast Management LP (0.01%), Nisa Investment Advisors LLC (0.00%) and IFP Advisors Inc (0.00%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Eilon D Kirson, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, William F Doyle and Yoram Palti. View Institutional Ownership Trends for Novocure.

Which major investors are selling Novocure stock?

NVCR stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC. Company insiders that have sold Novocure company stock in the last year include Asaf Danziger, Charles G Phillips III, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen and William F Doyle. View Insider Buying and Selling for Novocure.

Which major investors are buying Novocure stock?

NVCR stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Sciencast Management LP, Polianta Ltd, IFP Advisors Inc and Nisa Investment Advisors LLC. View Insider Buying and Selling for Novocure.

How do I buy shares of Novocure?

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Novocure's stock price today?

One share of NVCR stock can currently be purchased for approximately $92.58.

How big of a company is Novocure?

Novocure has a market capitalization of $9.16 billion and generates $248.07 million in revenue each year. The medical equipment provider earns $-63,560,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis. View Additional Information About Novocure.

What is Novocure's official website?

The official website for Novocure is http://www.novocure.com/.

How can I contact Novocure?

Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]


MarketBeat Community Rating for Novocure (NASDAQ NVCR)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  397 (Vote Outperform)
Underperform Votes:  373 (Vote Underperform)
Total Votes:  770
MarketBeat's community ratings are surveys of what our community members think about Novocure and other stocks. Vote "Outperform" if you believe NVCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Featured Article: Roth IRA

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel